- Advanced search
- Immuno Portal
- Malaria Portal
betamethasone is an approved drug (FDA (1961))
Compound class: Metabolite or derivative
Comment: Marketed medications may contain dipropionate (eg Diprosone® and Diprolene®), sodium phosphate (eg Bentelan®) or valerate (eg Betnovate® and Celestone®) formulations.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
View more information in the IUPHAR Pharmacology Education Project: betamethasone
|No information available.
|Summary of Clinical Use
|Betamethasone is a synthetic glucocorticoid receptor (GR) agonist, with anti-inflammatory, antipruritic, and vasoconstrictive activities. The drug is used to treat the inflammatory sympotoms of conditions including atopic, seborrhoeic, and contact dermatitis, psoriasis and insect bite reactions.
|Mechanism Of Action and Pharmacodynamic Effects
|As an agonist of the glucocorticoid receptor (GR), betamethasone modulates expression of genes containing the glucocorticoid response element (GRE). Although complex, the response appears to include inhibition of the biosynthesis of pro-inflammatory prostaglandins and leukotrienes.
For extended ADME data see the following:
Electronic Medicines Compendium (eMC)